Literature DB >> 17940479

Natural history of cerebral vein thrombosis.

Francesco Dentali1, Walter Ageno.   

Abstract

PURPOSE OF REVIEW: There is increasing information on the natural history of cerebral vein thrombosis. The objectives of this review are to evaluate the mortality rates and the rate of residual disability in cerebral vein thrombosis patients, to determine clinical and radiological predictors of death and dependence, and to estimate the cumulative incidence of recurrent cerebral vein thrombosis after a first episode. RECENT
FINDINGS: Mortality rates appear to be low during the acute phase or after follow-up. Most surviving patients recover completely or present only mild functional or cognitive deficits. Recanalization appears to occur within the first months following cerebral vein thrombosis, but not thereafter, irrespective of anticoagulation. Recurrences of cerebral vein thrombosis and other thromboembolic complications after a first episode are uncommon. Patients with intracranial hemorrhage at onset or patients with epileptic seizures seem to have an increased risk of death and residual disability in comparison with the other patients.
SUMMARY: Prognosis of cerebral vein thrombosis is better than previously believed. Mortality and residual disability are relevant in patients presenting with intracranial hemorrhage or with epileptic seizures. Although heparin is widely used as a first-line therapy of cerebral vein thrombosis, there is still scant evidence of its efficacy and safety in comparison with placebo.

Entities:  

Mesh:

Year:  2007        PMID: 17940479     DOI: 10.1097/MCP.0b013e3282058b81

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  1 in total

1.  Prolonged Microcatheter-Based Local Thrombolytic Infusion as a Salvage Treatment After Failed Endovascular Treatment for Cerebral Venous Thrombosis: A Multicenter Experience.

Authors:  Adnan I Qureshi; Mikayel Grigoryan; Muhammad A Saleem; Emrah Aytac; Shawn S Wallery; Gustavo J Rodriguez; Muhammad F K Suri
Journal:  Neurocrit Care       Date:  2018-08       Impact factor: 3.210

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.